<p>This is a summary of the European public assessment report (EPAR) for Descovy. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Descovy.</p><p>For practical information about using Descovy, patients should read the package leaflet or contact their doctor or pharmacist.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1).</p></div>
Therapeutic Area (MeSH)
ATC Code
J05AR17
ATC Item
N/A
Pharmacotherapeutic Group
Antivirals for systemic use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| emtricitabine | N/A | emtricitabine |
| tenofovir alafenamide | N/A | tenofovir alafenamide |
EMA Name
Descovy
Medicine Name
Descovy
Aliases
N/ANo risk management plan link.
